548 results on '"Khouri I"'
Search Results
2. Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL)
3. Bendamustine added to allogeneic conditioning improves long-term outcomes in patients with CLL.
4. Pattern of Reconstitution and Relapse Following Autologous Bone Marrow Transplantation for Chronic Myelogenous Leukemia
5. Blood Progenitor Cells and Donor Lymphocyte Transfusion: the New Modes of Marrow Transplantation
6. Outcomes in hepatitis C virus seropositive lymphoma and myeloma patients after autologous stem cell transplantation
7. Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR
8. High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin's lymphoma in patients >65 years of age
9. Infections in non-myeloablative hematopoietic stem cell transplantation patients with lymphoid malignancies: spectrum of infections, predictors of outcome and proposed guidelines for fungal infection prevention
10. Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial
11. Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome
12. Genetically identical twin transplantation for chronic lymphocytic leukemia
13. Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation
14. Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation
15. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies
16. High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation
17. Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies
18. Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia
19. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen
20. Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response
21. Stem cell transplantation for chronic lymphocytic leukemia: should not more patients get a transplant?
22. Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma
23. Low-dose alemtuzumab (Campath®) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics
24. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results
25. Non-Myeloablative Stem Cell Transplantation for Acute Myelogenous Leukemia
26. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma
27. Autistic symptoms following herpes encephalitis
28. Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study
29. Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation
30. Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma
31. Cytomegalovirus pneumonia in adult autologous blood and marrow transplant recipients
32. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease
33. High-dose melphalan and allogeneic peripheral blood stem cell transplantation for treatment of early relapse after allogeneic transplant
34. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation
35. Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia
36. Rituximab for passenger lymphocyte syndrome associated with allogeneic SCT
37. Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience
38. Toxicities of tacrolimus and cyclosporin A after allogeneic blood stem cell transplantation
39. Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir
40. Allogeneic blood stem cell transplantation in advanced hematologic cancers
41. Phase II study of unrelated cord blood transplantation for adults with high-riskhematologic malignancies
42. Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant
43. Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease
44. 9. Chronic Lymphocytic Leukaemia: 043 OUTCOME IN PATIENTS WITH RICHTERʼS SYNDROME TREATED WITH CHEMOTHERAPY AND/OR IMMUNOTHERAPY WITH OR WITHOUT STEM CELL TRANSPLANTATION
45. Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkinʼs lymphoma
46. Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma
47. Is there an increased rate of additional malignancies in patients with mantle cell lymphoma?
48. PS1564 HAPLOIDENTICAL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA PATIENTS WITH DETECTABLE DISEASE AT TRANSPLANT
49. PS1561 RITUXIMAB-BEAM AND AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) FOR PATIENTS (PTS) WITH RELAPSED FOLLICULAR LYMPHOMA (FL) NOT ABLE TO RECEIVE AN ALLOGENEIC SCT: 8-YEAR MEDIAN FOLLOW-UP RESULTS
50. PS1530 POST-TRANSPLANT CYCLOPHOSPHAMIDE IN HLA MATCHED AND HAPLOIDENTICAL TRANSPLANT RECIPIENTS RECEIVING MYELOABLATIVE TIMED SEQUENTIAL BUSULFAN CONDITIONING REGIMEN: RESULTS OF A PHASE II STUDY
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.